Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK4 | Q96L34 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 8/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CPT2 | P23786 | 1/20 | 0.50 |
| ▸ | CPT1A | P50416 | 1/20 | 0.50 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1923602 | 0.96 | CPT2 (0.55) | MARK4MAPTKMT2ATP53ALDH1A1 | |
| SCHEMBL1923429 | 0.94 | MAPT (0.55) | MARK4MAPTKMT2ATP53ALDH1A1 | |
| SCHEMBL1923492 | 0.94 | USP10 (0.53) | MARK4MAPTKMT2ATP53ALDH1A1 | |
| SCHEMBL1923524 | 0.90 | MAPT (0.55) | MARK4MAPTKMT2ATP53ALDH1A1 | |
| SCHEMBL1923426 | 0.88 | KDM4E (0.53) | MAPTKMT2ATP53ALDH1A1RXFP1 | |
| SCHEMBL1923521 | 0.88 | CPT2 (0.50) | MARK4MAPTKMT2ATP53ALDH1A1 | |
| SCHEMBL1923611 | 0.87 | CPT2 (0.49) | MARK4MAPTKMT2ATP53ALDH1A1 | |
| SCHEMBL1923318 | 0.86 | MAPT (0.53) | MAPTKMT2ATP53ALDH1A1RXFP1 | |
| SCHEMBL1923646 | 0.85 | USP10 (0.46) | MARK4MAPTKMT2ATP53RXFP1 | |
| SCHEMBL1923988 | 0.84 | MEN1 (0.45) | MARK4MAPTKMT2AALDH1A1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064185-B1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2011-06-08 | — | — | EP | claimed |
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-01 | — | — | US | claimed |
| CN-101522630-A | 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INT (ES) | 2009-09-02 | — | — | CN | claimed |
| EP-2064185-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | Ferrer Internacional, S.A. (ES) | 2009-06-03 | — | — | EP | claimed |
| WO-2008017710-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL S.A. (ES) | 2008-02-14 | — | — | WO | claimed |
| EP-1886996-A1 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-13 | — | — | EP | claimed |
| EP-2064185-B1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2011-06-08 | — | — | EP | disclosed |
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| CN-101522630-A | 1H-quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INT (ES) | 2009-09-02 | — | — | CN | disclosed |
| EP-2064185-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | Ferrer Internacional, S.A. (ES) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008017710-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL S.A. (ES) | 2008-02-14 | — | — | WO | disclosed |
| EP-1886996-A1 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | GABRA1, GABRA4, GABRA2 | MARK4 2609/4885MAPT 1569/4885KMT2A 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.